Clinical trials: Renal Allograft
Failing Renal Allograft
Belatacept Therapy for the Failing Renal Allograft
The purpose of this study is to test the safety and effectiveness of belatacept (Nulojix®) in preventing antibody formation in patients with chronic failing kidney transplants.
- Trial name
- IM103-133 (NCT01921218)
- Testing
- Belatacept, Calcineurin inhibitor therapy, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Andrew B Adams
Urinary Tract Infection, Asymptomatic Bacteriuria
Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation
Urinary tract infections (UTI) are the most common complications after kidney transplantation. Most series have reported incidence between 20 to 50% during the first year.
- Conditions
- Urinary Tract Infection, Asymptomatic Bacteriuria, Allograft Rejection, Microbiologic Resistance
- Trial name
- NCT01820897
- Testing
- Fosfomycin-Trometamol, Sulfamethoxazole trimethoprim
- Where
- 2 sites in Mexico
- Volunteers
- 130 people
- Sponsor
- JOSE MANUEL ARREOLA GUERRA
Diabetes Mellitus, Type 1
Islet Transplantation in Type 1 Diabetic Kidney Allograft
The purpose of this study is to learn about the safety of islet transplantation when performed after kidney transplantation, which may provide more normal control of blood sugar without the need for insulin shots.
- Trial name
- NCT01241864
- Testing
- Allogenic islet cells (human, U. Chicago), Intraportal infusion of islet cells
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Kidney Transplant Rejection
SRDK0921_ Analytical Performance Study
Analytical Performance Study of the SRDK0921 IVD medical device (Kit and Software)
- Trial name
- SRDK0921_APS (NCT05747274)
- Testing
- SRDK0921
- Where
- France
- Volunteers
- 439 people
- Sponsor
- BioMAdvanced Diagnostics
End Stage Chronic Renal Failure, Renal Transplant
Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function
This pilot study is testing a new ultrasound imaging method called Super-Resolution Ultrasound (SRU) to look at blood flow and tiny blood vessels in transplanted kidneys in very detailed images after kidney transplant surgery.
- Conditions
- End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
- Trial name
- MUST-D (NCT07645599)
- Testing
- Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Roderick Tan
Renal Failure
Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion
The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with kidney failure allowing a reduction or cessation of immune-suppressive therapy.
- Trial name
- NCT00498160
- Testing
- Enriched Hematopoietic Stem Cell Infusion
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Talaris Therapeutics Inc.
Antibody Mediated Rejection
A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).
The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with with active and chronic active renal allograft antibody mediated…
- Trial name
- NCT07641426
- Testing
- CID-103
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- CASI pharmaceuticals, Inc.
Renal Transplantation
Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients
To assess equivalence in the rates of functional graft survival at 12 months after transplantation in patients receiving continuous therapy with cyclosporine (CsA, Sandimmune, Neoral) and sirolimus versus induction with CsA and…
- Trial name
- NCT00428064
- Testing
- Sirolimus, cyclosporine
- Volunteers
- 408 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Kidney; Complications, Allograft
Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients
To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation in the…
- Trial name
- PROTECT (NCT02036554)
- Testing
- Everolimus, Tacrolimus, Mycophenolic acid
- Where
- South Korea
- Volunteers
- 234 people
- Sponsor
- Seoul St. Mary's Hospital
Kidney Transplantation, Graft Rejection
A Study on a New Staining Method (C4d Staining) of Transplanted Kidney Biopsies
Patients who had received kidney transplantation may suffer from rejection. Recently, positive staining for C4d in kidney biopsies of malfunctioning transplant kidney is increasingly recognized as an important prognostic…
- Trial name
- NCT00498095
- Testing
- Renal biopsy
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Hospital Authority, Hong Kong
Renal Transplantation
Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
Efficacy and safety of 2 groups of treatment: everolimus in association with cyclosporine microemulsion and steroids versus everolimus in association with Enteric-coated Mycophenolate Sodium (EC-MPS) and steroids.
- Trial name
- NCT00425308
- Testing
- Everolimus + Cyclosporine, Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS), Steroids
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant
A Study Of CP-690,550 In Stable Kidney Transplant Patients
This was a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients.
- Trial name
- NCT01710033
- Testing
- CP-690,550 5 mg BID, CP-690,550 15 mg BID, CP-690,550 30 mg BID
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pfizer
Chronic Rejection, Kidney Insufficiency
Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients
The purpose of this study is to determine if administration of rituximab blocks the development of donor specific antibodies (DSA) in transplant recipients who have developed renal dysfunction and DSA after renal transplant.
- Trial name
- NCT00261547
- Testing
- Rituximab
- Sponsor
- Massachusetts General Hospital
Kidney Transplantation
Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients
The aim of this trial is to compare the safety and efficacy of a single dose of Thymoglobulin, rabbit derived antithymocyte globulin (Thymoglobulin, SangStat, Fremont, CA) to our standard four dose, four day Thymoglobulin…
- Trial name
- NCT00235781
- Testing
- Thymoglobulin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Graft Rejection, Kidney Transplant
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
- Conditions
- Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
- Trial name
- NCT00895583
- Testing
- Tacrolimus, Sirolimus
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
Allosensitization, Kidney Transplant Rejection
Desensitization in Kidney Allograft Using Daratumumab
Patients highly allosensitized against HLA antigen awaiting for a kidney transplant have less compatible transplants to them, increasing their waitlist time and mortality.
- Conditions
- Allosensitization, Kidney Transplant Rejection, Antibody-mediated Rejection
- Trial name
- DARDAR (NCT04204980)
- Testing
- Daratumumab dose escalation, Daratumumab full dose
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplant; Complications
Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation
Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A.
- Trial name
- NCT07033858
- Testing
- Rapamune Pill
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Heart Transplantation
A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
This study will evaluate the efficacy and safety of intravenous daclizumab in combination with oral mycophenolate mofetil and oral sirolimus in participants receiving a heart transplant, and at risk of impaired kidney function.
- Trial name
- NCT02554955
- Testing
- Daclizumab, Mycophenolate mofetil, Silrolimus
- Where
- 14 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Kidney Transplantation, Diabetes Mellitus, Type 2
EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce plasma glucose and haemoglobin A1c(HbA1c) in patients with type 2 diabetes mellitus by increasing urinary glucose excretion in a non-insulin-dependent fashion.
- Conditions
- Kidney Transplantation, Diabetes Mellitus, Type 2, Diabetes Complications
- Trial name
- NCT04743453
- Testing
- Dapagliflozin
- Where
- Brazil
- Volunteers
- 211 people
- Sponsor
- University of Sao Paulo General Hospital
Kidney Transplantation
Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus
This study evaluated renal graft function (based on calcuated creatinine clearance) 12 months after transplantation in patients receiving either a regimen of reduced dose or standard dose cyclosporine in combination with…
- Trial name
- NCT00518375
- Testing
- Rapamune® (Sirolimus), Neoral® (Cyclosporine), Corticosteroids
- Volunteers
- 250 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer